Moberg Pharma AB (FRA:MB8) Total Current Assets: €21.82 Mil (As of Mar. 2026)


FRA:MB8 Moberg Pharma AB FRA:MB8
60 GF Score
Price €0.80
GF Value €1.04
! 1 Warning Sign
View Full Analysis

What is Moberg Pharma AB Total Current Assets?

Moberg Pharma AB FRA:MB8 -1.12% 60 Total Current Assets is €21.82 Mil as of Mar. 2026. GuruFocus rates FRA:MB8 with a GF Score™ of 60/100 and a GF Value™ of €1.04. The stock has 1 warning sign investors should review.

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Moberg Pharma AB's total current assets for the quarter that ended in Mar. 2026 was €21.82 Mil.

Moberg Pharma AB  (FRA:MB8) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Moberg Pharma AB's Liquidation Value for the quarter that ended in Mar. 2026 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=20.656-1.703+0.75 * 0.622+0.5 * 0.537
=19.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Moberg Pharma AB Total Current Assets Related Terms

Moberg Pharma AB Total Current Assets Historical Data

* Premium members only.

The historical data trend for Moberg Pharma AB's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Moberg Pharma AB Total Current Assets Chart

Moberg Pharma AB Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec21 Dec22 Dec23 Dec24
Total Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.63 10.19 11.62 6.21 26.09

Moberg Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.71 24.42 22.68 21.86 21.82
FRA:MB8
60GF Score
Moberg Pharma AB FRA:MB8
Total Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Moberg Pharma AB Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Moberg Pharma AB's Total Current Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=25.437+0.07+0.373+0.211
=26.09

Moberg Pharma AB's Total Current Assets for the quarter that ended in Mar. 2026 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=20.656+0.622+0.537+0.0010000000000012
=21.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Frequently Asked Questions Learn more about Total Current Assets →
What does a Total Current Assets of €21.82 Mil mean?
Moberg Pharma AB (FRA:MB8) has a Total Current Assets of €21.82 Mil as of Mar. 2026. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Moberg Pharma AB and its competitors.
Is Moberg Pharma AB's Total Current Assets too high?
Moberg Pharma AB's current Total Current Assets is €21.82 Mil. Overall, Moberg Pharma AB has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does Moberg Pharma AB's Total Current Assets compare to ZTS and UTHR?
Moberg Pharma AB's Total Current Assets of €21.82 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Assets for a Drug Manufacturers company?
A good Total Current Assets depends on the Drug Manufacturers industry context. However, Total Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Assets mean?
A high Total Current Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Moberg Pharma AB and its competitors. Moberg Pharma AB's current Total Current Assets is €21.82 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moberg Pharma AB stock overvalued right now?
Moberg Pharma AB (FRA:MB8) has a current Total Current Assets of €21.82 Mil. The stock's GF Value™ is €1.04, compared to a current price of €0.80 — trading 23.6% below its estimated fair value. The current Total Current Assets is €21.82 Mil. Moberg Pharma AB's overall GF Score™ is 60/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Assets calculated?
Total Current Assets is calculated from a company's financial statements. For Moberg Pharma AB (FRA:MB8), the current Total Current Assets is €21.82 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Moberg Pharma AB (FRA:MB8) Overvalued in 2026?

Based on GuruFocus' analysis, Moberg Pharma AB stock appears to be undervalued. The current stock price of €0.80 is trading 23.6% below its estimated GF Value™ of €1.04.

Key valuation signals for FRA:MB8:

  • Total Current Assets: €21.82 Mil
  • GF Value™: €1.04 vs. price of €0.80 (23.6% below fair value)
  • GF Score™: 60/100 with 1 warning sign

No single metric tells the full story. See the FRA:MB8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Moberg Pharma AB Business Description

Other Exchanges MBGPF:USAMOB:Sweden
Address Gustavslundsvagen 42, 5th Floor, Bromma, Stockholm, SWE, SE-167 51
Moberg Pharma AB is a Swedish pharmaceutical company which develops and commercializes proprietary pharmaceuticals based on proven substances. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.
60GF Score

Get the complete analysis for FRA:MB8

Total Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.80
Price
€1.04
GF Value